English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

It has been established by the work ofmany authors that when progesterone is administered for periods of 1-3 days to human subjects in whom endogenous progesterone production is minimal, the amount of pregnanediol subsequently excreted in the urine accounts for only a small proportion (usually < 20%) ofthe administered hormone. In the preceding paper (Sommerville & Marrian, 1950) previous work in this field was comprehensively reviewed and it was shown in an extensive series of experiments on normal men, post-menopausal and hysterectomized women that about 9-16% of intramuscularly injected progesterone is excreted as urinary pregnanediol, and that a slightly higher proportion ofthe latter is excreted when progesterone is administered orally. Venning & Browne (1938, 1940) showed that the administration of progesterone during the luteal phase of the menstrual cycle and during pregnancy, at times when 'the process of conversion of progesterone to pregnanediol was already in action', resulted in the excretion ofa much higher proportion of the administered hormone as pregnanediol additional to that arising from endogenous sources. More recently, the greater efficiency of conversion of administered progesterone to urinary pregnanediol by the pregnant woman compared to that of women with minimal endogenous progesterone production has been confirmed by Davis & Fugo (1947), who reported that 30-35% of progesterone injected during early pregnancy was excreted as 'additional' pregnanediol. These authors came to the important conclusion that the 'activity of the corpus luteum must exert some effect on the metabolism of progesterone so that a much greater percentage can be accounted for as the inert metabolite pregnandiol'. In view of the possibility that the 'activity of the corpus luteum' responsible, according to Davis & Fugo (1947) for this phenomenon, might be the

Urinary excretion of pregnanediol in human subjects following the administration of progesterone and of pregnane-3α:20α-diol. 1